bat spit drug firm goes to market a german firm whose main product is derived from the saliva of the vampire bat is looking to raise more than 70m euros 91m 49m on the stock market. the firm, paion, said that it hoped to sell 5 million shares a third of the firm for 11 14 euros a share.